*ST Longjin: Announcement on the holding subsidiary obtaining a drug registration certificate
*ST Longjin: Announcement on Abnormal Fluctuations in Stock Trading
*ST Longjin: 2024 Third Quarter Report
*ST Longjin: Announcement on Abnormal Fluctuations in Stock Trading
*ST Longjin: Announcement on Abnormal Fluctuations in Stock Trading
*ST Longjin: 2024 Semi-Annual Report Summary
*ST Longjin: Semi-annual summary of non-operating capital expenditure and other related capital transactions
*ST Longjin: 2024 Semi-Annual Report
Kunming Longjin Pharmaceutical: Stock trading has experienced abnormal fluctuations announcement.
Kunming Longjin Pharmaceutical: Stock trading has experienced abnormal fluctuations announcement.
Kunming Longjin Pharmaceutical: Stock trading has experienced abnormal fluctuations announcement.
Kunming Longjin Pharmaceutical: 2024 Interim Performance Forecast
Kunming Longjin Pharmaceutical: Announcement on the Implementation of Shareholding Reduction by Shareholders.
Kunming Longjin Pharmaceutical: Stock trading has experienced abnormal fluctuations announcement.
Kunming Longjin Pharmaceutical: Stock trading has experienced abnormal fluctuations announcement.
Kunming Longjin Pharmaceutical: Notice of abnormal fluctuations in stock trading
Kunming Longjin Pharmaceutical: Response from China Audit Zhonghuan Certified Public Accountants (Special General Partnership) to the inquiry letter on the 2023 annual report of Kunming Longjin Pharmaceutical Co., Ltd.
Kunming Longjin Pharmaceutical: Notice of Response to the 2023 Annual Report Inquiry Letter
Kunming Longjin Pharmaceutical: Notice of abnormal fluctuations in stock trading
Kunming Longjin Pharmaceutical: 2023 Annual General Meeting of Shareholders Legal Opinions
No Data
No Data